What is the role for maintenance lenalidomide in elderly patients with DLBCL?
2
1 Answers
Mednet Member
Medical Oncology · University of North Carolina Chapel Hill School of Medicine
The REMARC study was a phase III trial of maintenance with lenalidomide versus placebo in patients aged 60-80 years old who were in a PR or CR after RCHOP for newly diagnosed DLBCL (Thieblemont et al. JCO 35:2471-2481, 2017.). The results of this large study (650pts) with a median follow up of over ...